Transition Therapeutics Inc. (CIK: 0001399250) EDGAR, Information, Filings... CompaniesBIO.Com

Transition Therapeutics Inc.

Mailing address
101 COLLEGE STREET, SUITE 220, TORONTO, A6, M5G 1L7
Phone
416-260-7770
State location
A6
State of incorporation
N/A
Fiscal year end
June 30
SIC
2833 - (CF Office: Office of Life Sciences) MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Filings
N/A

Transition Therapeutics Inc. (CIK: 0001399250) is an American company incorporated in the state of A6. Head office is located at 101 COLLEGE STREET, SUITE 220, TORONTO, A6, M5G 1L7. Work in the industry 2833 - (CF Office: Office of Life Sciences) MEDICINAL CHEMICALS & BOTANICAL PRODUCTS. Transition Therapeutics Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
SCHULER JACK W	0001021412	Dec-06-2010	10 percent owner
Schuler Family Foundation	0001512977	Dec-06-2010	10 percent owner

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Transition Therapeutics Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000315066-16-006297 (34 Act) Size: KB	Oct-11-2016	005-83093 161930696
15-12B	Document	Notice of termination of registration of a class of securities under Section 12(b) Acc-no: 0001144204-16-123758 (34 Act) Size: KB	Sep-13-2016	001-33514 161883457
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001144204-16-123756 (33 Act) Size: KB	Sep-13-2016	333-157279 161883446
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001144204-16-123362 (34 Act) Size: KB	Sep-09-2016	001-33514 161878543
25-NSE	Document	Acc-no: 0001354457-16-000476 (34 Act) Size: KB	Aug-31-2016	001-33514 161862030
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001144204-16-122185 (34 Act) Size: KB	Aug-31-2016	001-33514 161861886
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001144204-16-121286 (34 Act) Size: KB	Aug-26-2016	001-33514 161852580
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001144204-16-116598 (34 Act) Size: KB	Aug-04-2016	001-33514 161807376
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001144204-16-112835 (34 Act) Size: KB	Jul-13-2016	001-33514 161766007
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001144204-16-111756 (34 Act) Size: KB	Jul-06-2016	001-33514 161754775
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001144204-16-110690 (34 Act) Size: KB	Jun-30-2016	001-33514 161740512
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001279569-16-003662 (34 Act) Size: KB	Jun-03-2016	001-33514 161694297
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001144204-16-100873 (34 Act) Size: KB	May-11-2016	001-33514 161640351
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001279569-16-003412 (34 Act) Size: KB	May-09-2016	001-33514 161632329
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001279569-16-003248 (34 Act) Size: KB	Apr-26-2016	001-33514 161590650
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001279569-16-003204 (34 Act) Size: KB	Apr-18-2016	001-33514 161575859
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001279569-16-002999 (34 Act) Size: KB	Mar-24-2016	001-33514 161525385
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001279569-16-002808 (34 Act) Size: KB	Mar-01-2016	001-33514 161474090
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000315066-16-005543 (34 Act) Size: KB	Feb-12-2016	005-83093 161415318
SC 13D/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0001144204-16-080944 (34 Act) Size: KB	Feb-11-2016	005-83093 161412862

Recent 20 filings. View all Transition Therapeutics Inc. filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Transition Therapeutics Inc. overview
Transition Therapeutics Inc. job
Transition Therapeutics Inc. stock
Transition Therapeutics Inc. ownership
Transition Therapeutics Inc. CEO
Transition Therapeutics Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.